Teva Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries (TEVA), has announced a strategic partnership with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203. This candidate, a biosimilar to Eylea developed by Formycon, will be marketed in Europe (with Italy excluded) and Israel. Klinge holds the global rights for commercialization of FYB203, licensed from Formycon.
Under this agreement, Teva will take the lead in commercializing FYB203 within the specified regions, where it will be sold under the brand name AHZANTIVE3. As part of this collaboration, Klinge is set to receive milestone payments in addition to a share of the revenue generated from the product sales.
